Affordable Access

Access to the full text

Therapeutical interference with the epigenetic landscape of germ cell tumors: a comparative drug study and new mechanistical insights

Authors
  • Müller, Melanie R.1
  • Burmeister, Aaron1
  • Skowron, Margaretha A.1
  • Stephan, Alexa1
  • Bremmer, Felix2
  • Wakileh, Gamal A.1, 3
  • Petzsch, Patrick4
  • Köhrer, Karl4
  • Albers, Peter4
  • Nettersheim, Daniel1
  • 1 Heinrich Heine University Düsseldorf, Universitätsstr. 1, Düsseldorf, 40225, Germany , Düsseldorf (Germany)
  • 2 University Medical Centre Göttingen, Göttingen, Germany , Göttingen (Germany)
  • 3 University Hospital Ulm, Ulm, Germany , Ulm (Germany)
  • 4 Heinrich Heine University Düsseldorf, Düsseldorf, Germany , Düsseldorf (Germany)
Type
Published Article
Journal
Clinical Epigenetics
Publisher
Springer-Verlag
Publication Date
Jan 07, 2022
Volume
14
Issue
1
Identifiers
DOI: 10.1186/s13148-021-01223-1
Source
Springer Nature
Keywords
Disciplines
  • Research
License
Green

Abstract

BackgroundType II germ cell tumors (GCT) are the most common solid cancers in males of age 15 to 35 years. Treatment of these tumors includes cisplatin-based therapy achieving high cure rates, but also leading to late toxicities. As mainly young men are suffering from GCTs, late toxicities play a major role regarding life expectancy, and the development of therapy resistance emphasizes the need for alternative therapeutic options. GCTs are highly susceptible to interference with the epigenetic landscape; therefore, this study focuses on screening of drugs against epigenetic factors as a treatment option for GCTs.ResultsWe present seven different epigenetic inhibitors efficiently decreasing cell viability in GCT cell lines including cisplatin-resistant subclones at low concentrations by targeting epigenetic modifiers and interactors, like histone deacetylases (Quisinostat), histone demethylases (JIB-04), histone methyltransferases (Chaetocin), epigenetic readers (MZ-1, LP99) and polycomb-repressive complexes (PRT4165, GSK343). Mass spectrometry-based analyses of the histone modification landscape revealed effects beyond the expected mode-of-action of each drug, suggesting a wider spectrum of activity than initially assumed. Moreover, we characterized the effects of each drug on the transcriptome of GCT cells by RNA sequencing and found common deregulations in gene expression of ion transporters and DNA-binding factors. A kinase array revealed deregulations of signaling pathways, like cAMP, JAK-STAT and WNT.ConclusionOur study identified seven drugs against epigenetic modifiers to treat cisplatin-resistant GCTs. Further, we extensively analyzed off-target effects and modes-of-action, which are important for risk assessment of the individual drugs.

Report this publication

Statistics

Seen <100 times